INTRODUCTION
============

Proper development and function of the heart is dependent upon an intricate network of molecular cues and morphogenetic events that are highly conserved among vertebrates ([@b38-0040607]; [@b90-0040607]). The fact that congenital heart defects are among the most common congenital malformations highlights the exquisite sensitivity of heart formation to alterations in these formative events ([@b15-0040607]; [@b76-0040607]).

Studies of early cardiogenesis have identified a number of essential transcriptional mediators, growth factors and myofibrillar components that are required for the initial patterning of the heart ([@b65-0040607]; [@b89-0040607]; [@b90-0040607]). The embryonic heart begins to function before its development is complete, and many studies suggest that structure and function are inextricably linked, as they are in the adult heart ([@b36-0040607]; [@b42-0040607]; [@b43-0040607]; [@b81-0040607]; [@b96-0040607]). Some aspects of embryonic heart development (such as trabeculation and perhaps endocardial cushion (EC) formation and valve morphogenesis) are sensitive to embryonic function, whereas others (such as looping) do not seem to be dependent on physiological inputs ([@b2-0040607]; [@b9-0040607]; [@b10-0040607]; [@b13-0040607]; [@b17-0040607]; [@b26-0040607]; [@b36-0040607]; [@b41-0040607]; [@b61-0040607]; [@b83-0040607]; [@b97-0040607]; [@b98-0040607]). However, Sultana and colleagues recently demonstrated that early cardiac function is dispensable for valve morphogenesis ([@b91-0040607]), so the precise extent of the interactions between form and function during cardiogenesis, as well as the factors responsible for these interactions, remain to be determined.

Over the last few decades much has been learned of the factors regulating the structural and functional responses of the adult heart to a broad range of stimuli ([@b24-0040607]; [@b33-0040607]; [@b39-0040607]; [@b99-0040607]). The importance of elucidating the mechanisms of early cardiac functional patterning is underscored by the prominent redeployment of the fetal gene expression program early in the onset of hypertrophy in the adult heart ([@b66-0040607]). Indeed, inhibition of reactivation of the fetal gene expression program attenuates the induction of hypertrophy in animal models of pathological cardiac hypertrophy ([@b3-0040607]; [@b8-0040607]; [@b51-0040607]; [@b53-0040607]; [@b59-0040607]; [@b64-0040607]; [@b102-0040607]). There are also emerging data that implicate electrical and Ca^2+^ transients in the normal function and morphogenetic maturation of the developing heart, although unraveling these signals from their downstream mechanical effectors is challenging ([@b12-0040607]; [@b22-0040607]; [@b68-0040607]).

Here we report the identification and characterization of a previously unknown, evolutionarily conserved gene, heart adaptor protein 1 (*Hadp1*) in vertebrates. *Hadp1* expression is enriched in the vertebrate embryonic heart, and the gene dosage of *hadp1* affects cardiac function in the zebrafish embryo. Maximal loss of *hadp1* induces morphological defects, such as abnormal looping and aberrant atrioventricular (AV) canal (AVC) formation. Using high-resolution physiological measurements, optical voltage mapping and Fura-2-based ratiometric calcium (Ca^2+^) imaging, we show that cardiac contractility, conduction and Ca^2+^ handling are exquisitely sensitive to *hadp1* gene dosage. We demonstrate that HADP1 is a membrane-bound, pleckstrin homology (PH)-domain protein that interacts with phosphatidylinositol derivatives. Finally, we present in vivo pharmacological data implicating PI4-kinase (PI4K) as an upstream regulator of Hadp1 function in the heart. Together, these results indicate that Hadp1 interacts with the PI4K pathway to regulate normal Ca^2+^ dynamics, and thus myocardial contractility and differentiation, within the embryonic zebrafish heart.

RESULTS
=======

*Hadp1* is expressed in the vertebrate heart
--------------------------------------------

To identify genes involved in regulating vertebrate heart development, gene expression changes were analyzed in cardiomyocytes that were isolated from various stages of fetal and postnatal rat hearts ([@b63-0040607]). An amplicon representing *Hadp1* was present at high levels in the fetal cardiomyocyte pool, but was undetectable in postnatal day (P)12 rat cardiomyocytes (supplementary material Fig. S1A,B). Northern analysis showed that expression of *Hadp1* is enriched in the embryonic, but not adult, heart in humans and mice (supplementary material Fig. S1B,C). cDNA library screening, northern analysis and rapid amplification of cDNA ends (RACE) determined that alternative splicing occurs at the 5′ end of mammalian *Hadp1* to generate two transcripts, *Hadp1a* and *Hadp1b* (supplementary material Fig. S1E). Northern analysis and reverse-transcriptase PCR (RT-PCR) determined that expression of both transcripts (*Hadp1a* and *Hadp1b*) is enriched at similar levels in the embryonic but not adult heart in rats, mice and humans (supplementary material Fig. S1F,G, and data not shown). Probes designed against the region predicted to be common to both splice variants of *Hadp1* also identified two transcripts in zebrafish (supplementary material Fig. S1H). However, 5′ RACE originating in this same region yielded only one transcript in zebrafish embryos (data not shown). Interestingly, RT-PCR determined that *hadp1* expression is maintained in the adult zebrafish heart, unlike in mammals (data not shown). Zebrafish *hadp1* is the true homolog of murine *Hadp1*: synteny is conserved and the protein is 55% identical (60% similar) to murine HADP1a ([Fig. 1A](#f1-0040607){ref-type="fig"}; supplementary material Figs S2 and S3). HADP1a contains two WW domains, a PH domain ([@b58-0040607]; [@b93-0040607]), two polyproline-rich stretches and an ATP/GTP-binding motif (P-loop) at the N-terminus, and an ATP-binding cassette/structural maintenance of chromosomes (ABC_SMC) domain at the C-terminus ([Fig. 1A](#f1-0040607){ref-type="fig"}).

*hadp1* is expressed in zebrafish during early somitogenesis (four- to six-somite stage) in the posterior region of the tailbud. Expression in the heart is detectable at the 18- to 20-somite stage, after the bilateral fields of cardiomyocyte progenitors have migrated from the lateral plate mesoderm and coalesced at the midline to form the linear heart tube ([Fig. 1B--H](#f1-0040607){ref-type="fig"}). *hadp1* transcripts are present throughout the heart until 72 hours postfertilization (hpf) ([Fig. 1I--N](#f1-0040607){ref-type="fig"}). At 72 hpf, *hadp1* expression became restricted to the ventricle, with no evidence of expression in the atrium ([Fig. 1N](#f1-0040607){ref-type="fig"}). Serial sectioning of 72-hpf embryos following whole-mount in situ hybridization (WISH) showed no atrial expression and confirmed that *hadp1* was localized to the ventricular myocardium (supplementary material Fig. S4). Examination of various embryonic stages of murine development by WISH revealed expression of *Hadp1* throughout all chambers of the heart, unlike its zebrafish ortholog (supplementary material Fig. S5).

![**Expression of *hadp1*, a newly identified PH-domain family gene, is enriched in the embryonic zebrafish heart.** (A) Predicted secondary structure of murine HADP1 with the percent amino acid similarity of zebrafish Hadp1 shown below. WW, WW motif; PH, pleckstrin-homology domain; Pro, proline-rich region; A/G, ATP/GTP-binding motif A; SMC, ATP-binding cassette/structural maintenance of chromosomes family ATPase domain. (B--N) Whole mount in situ hybridization for *hadp1* in zebrafish. (B--D,F,I) Lateral view; (E) lateral view on left and dorsal view on right; (G,H) lateral view on left and anterior view on right; (J) dorsal view; (K,M) lateral view on left and ventral view on right; (L,N) close-up of ventral view. The heart is indicated with an arrow (G--K,M). The ventricle (V) and atrium (A) are indicated.](DMM002204F1){#f1-0040607}

Given the high degree of conservation of Hadp1 between multiple species (supplementary material Figs S2, S3), as well as its robust expression in the developing vertebrate heart, we chose to pursue loss-of-function studies of Hadp1 in zebrafish because of the ability to characterize interactions between cardiac morphogenesis, physiology and electrical activity in vivo during the earliest stages of development.

*hadp1* is required for cardiovascular function in zebrafish
------------------------------------------------------------

A splice-blocking morpholino (*hadp1*SBMO1; hereafter referred to as SBMO1) was designed against an exon-intron boundary (common to both predicted transcripts) of *hadp1* to disrupt the in vivo function of Hadp1 ([@b28-0040607]). Efficacy of the morpholino was determined by RT-PCR of RNA isolated from MO-injected embryos. SBMO1-injected embryos produced a single, aberrant *hadp1* transcript lacking exon 6 ([Fig. 2A,B](#f2-0040607){ref-type="fig"}). Loss of the N-terminus of a PH domain \[as occurs in the predicted product of the SBMO1 transcript (data not shown)\] often abrogates PH-domain folding and recognition of their phosphatidylinositol binding partners ([@b34-0040607]; [@b46-0040607]; [@b55-0040607]; [@b74-0040607]; [@b77-0040607]).

*hadp1* morphant embryos appeared morphologically indistinguishable from control MO-injected embryos throughout the first 24 hours of development. At 48 hpf, embryos injected with SBMO1 displayed blood pooling just below the atrium and showed pericardial edema, abnormalities that were not observed in control embryos ([Fig. 2C,D](#f2-0040607){ref-type="fig"}). At 55 hpf, SBMO1 morphants displayed bradycardia and reduced cardiac output (as determined by fractional shortening; data not shown) (supplementary material Movies 1, 2).

To determine the extent of altered blood flow in *hadp1* morphants, we scored circulation in live 30- to 36-hpf embryos by microangiography. Normally, dye injected into the common cardinal vein (CCV) is drawn into the heart, passes through the aortic arches, into the dorsal aorta (DA) and returns via the posterior cardinal vein (PCV). In 87% of SBMO1 morphants (*n*=212), however, the dye pooled in the CCV and failed to circulate. Only 13% of control-injected embryos (*n*=107), and 5% of wild-type embryos (*n*=134) exhibited a similar phenotype ([Fig. 2E--G](#f2-0040607){ref-type="fig"}). Knockdown of *hadp1* in the endothelial-specific reporter line Tg(*fli*:EGFP)^y1^ ([@b54-0040607]) demonstrated that loss of *hadp1* did not affect vascular patterning (*n*=30 for each treatment) ([Fig. 2H--L](#f2-0040607){ref-type="fig"}). Thus, altered circulation in the morphants was not the consequence of a compromised vascular system.

Because ectopic expression of *hadp1* caused severe gastrulation defects, it was impossible to clearly rescue the effects of gene knockdown by widespread overexpression (data not shown). To confirm that the observed physiological defects were a result of *hadp1* loss and were not off-target effects, embryos were injected with a second, non-overlapping MO, *hadp1*SBMO2 (SBMO2). SBMO2-injected embryos produced reduced levels of wild-type *hadp1* transcript, along with an alternative transcript (supplementary material Fig. S6A,B) that lacked exon 5 and encoded a predicted premature termination product (data not shown). These animals displayed pericardial edema and circulatory defects at a penetrance similar to that seen in SBMO1 morphants (supplementary material Fig. S6C-I). Thus, elimination of wild-type *hadp1* and production of either a truncated Hadp1 protein (SBMO2) or a mutant form of the protein that probably cannot interact with phosphoinositides (SBMO1) resulted in embryos with altered cardiac function. Collectively, these results demonstrate that *hadp1* is required for normal cardiovascular function in zebrafish.

Loss of *hadp1* induces dose-dependent bradycardia and contractility defects
----------------------------------------------------------------------------

Knockdown of Hadp1 with higher doses (10 ng/embryo) of SBMO1 caused various morphological defects (unlooped hearts, AVC defects, pericardial edema and diminished contractility) ([Fig. 2](#f2-0040607){ref-type="fig"}; see below; supplementary material Fig. S6). To uncover the processes most sensitive to loss of *hadp1*, we developed conditions of partially reduced *hadp1* levels. Injection of 1 or 2 ng of SBMO1 did not induce pericardial effusion, blood pooling (data not shown and supplementary material Movies 3--5) or altered cardiac morphogenesis (data not shown). However, these manipulations still affected cardiac performance, as analyzed by heart rate in live embryos, with a dose-dependent relationship between loss of *hadp1* and decreased heart rate \[control: 186 beats/minute (bpm), *n*=5; 1 ng: 173 bpm, *n*=6, *P*\<0.05; 2 ng: 149 bpm, *n*=5, *P*\<0.001) ([Fig. 3A](#f3-0040607){ref-type="fig"}).

![**Knockdown of *hadp1* decreases cardiac output and contractility in zebrafish.** (A,B) Schematic representation of Hadp1 protein (top) and partial genomic structures (bottom; boxes represent coding exons), with positions of the MO and RT-PCR primers indicated. See [Fig. 1](#f1-0040607){ref-type="fig"} for abbreviations. (B) RT-PCR analysis of control and morphant embryos. β*-actin* is a loading control. --RT indicates the absence of reverse transcriptase as a negative control. (C,D) Brightfield images of live embryos (anterior is to the left) after injection with 10 ng control MO or 10 ng SBMO1. Arrow and arrowhead indicate pericardial effusion and blood pooling, respectively. (E,F) Microangiography following injection of control MO or SBMO1 reveals that circulation is altered following knockdown of *hadp1*. Heart (H), common cardinal vein (CCV), dorsal aorta (DA) and the posterior cardinal vein (PCV) are indicated. Circulation was scored by microangiography, or under transmitted light, and the results are quantified in G. (H--K) Confocal micrographs of control MO or SBMO1 morphant *fli:*EGFP transgenic embryos. Dorsal aorta (DA), posterior cardinal vein (PCV), parachordal vein (PAV), intersegmental arteries (ISA), intersegmental vessel (ISV) and dorsal longitudinal anastomotic vessel (DLAV) are indicated. (L) Quantification of normal vascular patterning.](DMM002204F2){#f2-0040607}

To objectively monitor ventricular function, we measured myocardial fractional shortening, in the context of reduced doses of SBMO1 ([Fig. 3B](#f3-0040607){ref-type="fig"}). Cardiac fractional shortening was significantly reduced in embryos injected with 1 ng (24±3%, *n*=5, *P*\<0.001; mean ± s.e.m.) or 2 ng (20±2%, *n*=7, *P*\<0.001) of SBMO1 when compared with control-MO-injected (10 ng) embryos (44±4%, *n*=4) ([Fig. 3C](#f3-0040607){ref-type="fig"}) (supplementary material Movies 3--5). These results demonstrate that reduction of *hadp1* expression, with doses of morpholino that do not elicit confounding morphological phenotypes, leads to diminished heart rate and depressed indices of ventricular contractility.

Loss of *hadp1* does not alter heart field specification or cardiomyocyte number
--------------------------------------------------------------------------------

In an effort to ascertain the underlying cause of altered cardiac function following loss of *hadp1*, we examined the earliest steps in embryonic cardiac development. Complete loss of *hadp1* did not alter cardiomyocyte cell specification, nor did it affect cardiomyocyte migration or fusion into the linear heart tube ([Fig. 4A--H](#f4-0040607){ref-type="fig"}). Expression of the cardiac transcription factor *nkx2.*5, as well as the contractile protein gene *cmlc2*, a definitive cardiomyocyte marker, was indistinguishable between embryos injected with high doses of SBMO1 and embryos injected with control MO. Furthermore, *nkx2.5* expression was not altered at 30 hpf in morphants, demonstrating that heart tube extension was unaffected by the loss of *hadp1* ([Fig. 4I,J](#f4-0040607){ref-type="fig"}). These results demonstrate that induction of the cardiac progenitor program, heart tube fusion and heart tube extension are all unaffected by loss of *hadp1*.

Because *hadp1* was identified initially in proliferating cardiomyocytes, we investigated whether loss of *hadp1* affected cardiomyocyte proliferation. *cmlc2*:GFP embryos, which express GFP in atrial and ventricular cardiomyocytes ([@b44-0040607]), were injected with SBMO1, and GFP-positive cells were counted at 36 and 48 hpf. Although circulation defects were apparent from 30 hpf onwards, the mean number of GFP-positive cells at either time point was indistinguishable between control-injected embryos (36 hpf: 203, *n*=22; 48 hpf: 276, *n*=6) ([Fig. 4K--O](#f4-0040607){ref-type="fig"}) and *hadp1* morphants (36 hpf: 196, *n*=28; 48 hpf: 272, *n*=6), as was the mean number of phosphorylated Histone H3 (H3P)-positive cells in the 48-hpf heart (3.5 vs 4.0, respectively; *P*=0.63) ([Fig. 4P--R](#f4-0040607){ref-type="fig"}). In addition, the endocardium and myocardium of the atrium and ventricle were indistinguishable between control-MO and SBMO1 (*n*=12 for each treatment) embryos, demonstrating that basic morphogenesis occurs normally in the absence of *hadp1* ([Fig. 4S--V](#f4-0040607){ref-type="fig"}). Examination of 48-hpf morphant hearts by transmission electron microscopy (TEM) revealed no evidence of defects in the sarcomeric ultrastructure of *hadp1* morphants (*n*=6 for control MO; *n*=6 for SBMO1; [Fig. 4W,X](#f4-0040607){ref-type="fig"}).

*hadp1* is required for AVC myocardial differentiation
------------------------------------------------------

Owing to the absence of defects in early cardiogenesis, we next investigated whether the circulatory abnormalities observed at high doses of *hadp1* knockdown resulted from loss of chamber identity, which might lead to perturbation of cardiac rhythm and abnormal contractility. Double in situ hybridization for an atrial-specific marker, *atrial myosin heavy chain* (*amhc*), and a ventricle-specific marker, *ventricular myosin heavy chain* (*vmhc*), revealed that the expression patterns of both genes were normal in SBMO1 embryos (control MO, *n*=30; SBMO1, *n*=50) ([Fig. 5A,B](#f5-0040607){ref-type="fig"}), although the hearts themselves appeared straighter and sometimes failed to undergo normal looping (data not shown). Immunohistochemical analysis to detect a pan-cardiac myosin (MF20) and an atrial-specific myosin (S46) further confirmed that neither atrial nor ventricular chamber identity is affected following loss of *hadp1* (control MO, *n*=15; SBMO1, *n*=25; [Fig. 5C,D](#f5-0040607){ref-type="fig"}).

As cardiac development proceeds in zebrafish, several changes occur within the chamber myocardium and in the AV boundary (or AVC) separating the two chambers (from which the endocardial lining will invaginate and develop into the valves of the heart to prevent retrograde blood flow) ([@b78-0040607]). Prior to ∼36 hpf, *bmp4* and *versican* are expressed throughout the anterior-posterior extent of the myocardium, and *notch1b* throughout the endocardium. However, by ∼37--48 hpf, expression of these genes becomes restricted to the AVC myocardium and endocardium, respectively, prior to EC formation at 72 hpf ([@b42-0040607]; [@b71-0040607]; [@b97-0040607]; [@b98-0040607]). In *hadp1* morphants (*n*=40), but not control embryos (*n*=60), the myocardial component of this restriction of gene expression failed to occur: the expression domain of *bmp4* encompassed the entire ventricle as late as 72 hpf ([Fig. 5E,F](#f5-0040607){ref-type="fig"}). Interestingly, restriction of the endocardial marker *notch1b* occurred normally at 48 hpf in *hadp1* morphants (*n*=24), compared with control-MO-injected embryos (*n*=24). These data indicate that myocardial and endocardial cross-talk and AVC development was impaired in some (Bmp, Wnt) signaling pathways, but not others (Notch) ([Fig. 5K,L](#f5-0040607){ref-type="fig"}).

![**Loss of *hadp1*leads to bradycardia and hypocontractility.** (A) Heart rate analysis (bpm) in control and *hadp1* morphants at 48 hpf and 21°C. (B) Live, lateral image of a 48-hpf zebrafish heart. The longest line represents the demarcation between the atrium (A) and ventricle (V), whereas the long line in the ventricle represents the end diastolic, or largest area, of the ventricular chamber and the shorter line represents the end systolic, or smallest, ventricular area. The ratio of these two measurements defines ventricular fractional shortening. (C) Analysis of ventricular fractional shortening following loss of *hadp1*. See supplementary material Movies 3, 4 and 5 for the absence of edema, unlike SBMO1 (10 ng)-injected animals (as shown in [Fig. 2](#f2-0040607){ref-type="fig"} and supplementary material Movies 1 and 2). \**P*≤0.05; \*\**P*≤0.005; \*\*\**P*≤0.001; ns, not significant.](DMM002204F3){#f3-0040607}

![**Cardiogenesis is not altered in *hadp1* morphants.** (A,B) Early specification of the heart field was analyzed by in situ hybridization for *nkx2.5* at the 10- to 12-somite stage. Arrowheads indicate *nkx2.5* expression. Embryos were stage-matched according to somite number as determined by *myoD* staining (indicated by the arrows). (C,D) Specification was also examined by in situ hybridization for *cmcl2* at the 15-somite stage. (E--H) Migration of cardiomyocytes to the midline was examined in 18- to 20-somite-stage embryos following loss of *hadp1* by in situ hybridization for *cmlc2* (E,F) and *nkx2.5* (G,H). (I,J) Heart-tube elongation and extension was assessed in 30-hpf control and *hadp1* morphant embryos by in situ hybridization for *nkx2.5*. (K--N) Direct immunofluorescence (K,L) and confocal microscopy (M,N) of *cmlc2*:GFP hearts from 36 hpf (K,L) and 48 hpf (M,N) control and *hadp1* morphant embryos. (O) The number of GFP+ cells was quantified. (P,Q) Confocal analysis of vibratome sectioned hearts following immunostaining for H3P and GFP in 48-hpf control (P) and *hadp1* morphant (Q) embryos. (R) The number of double-positive (H3P+, GFP+; i.e. proliferating cardiomyocytes) was quantified. (S--V) Coronal sections through the heart at 48 hpf, stained with hematoxylin and eosin, anterior to the top. Arrow and arrowhead indicate myocardium and endocardium, respectively. (S,T) Comparison of sections through the atrium of control (S) and *hadp1* morphant (T) embryos. (U,V) Comparison of sections through the ventricle of control (U) and *hadp1* morphant (V) embryos. (W,X) Coronal section at 48 hpf through cardiomyocytes viewed by TEM. Cardiomyocytes in control (W) and *hadp1* morphant (X) ventricles contain organized myofibrillar arrays.](DMM002204F4){#f4-0040607}

Cell morphological changes also differentiate atrial and ventricular myocardium ([@b2-0040607]; [@b68-0040607]), as well as AVC myocardium and endocardium. Specifically, as the heart develops, myocardium of the AVC becomes more trapezoidal, and endocardial cells of the AVC become more cuboidal ([@b13-0040607]; [@b22-0040607]; [@b20-0040607]; [@b21-0040607]; [@b97-0040607]). Concomitant with these morphological changes is the redistribution of a transmembrane adhesion molecule of the immunoglobulin superfamily, DM-grasp (Alcam, CD166) ([@b16-0040607]). DM-grasp expression is upregulated in the AVC myocardium and becomes localized to the lateral edges of myocardial cells in the AVC. Similarly, the cuboidal endocardial cells within the AVC are identified by their lateral expression of DM-grasp ([@b13-0040607]; [@b18-0040607]; [@b78-0040607]). Together, these gene expression and cellular changes are indicative of AVC and chamber myocardial and endocardial differentiation beginning at 48 hpf.

![**Non-chamber myocardium fails to differentiate properly in *hadp1* morphants.** (A--J) Frontal views at 48 hpf (head to the top) illustrate expression of chamber-specific genes in control and *hadp1* morphant embryos. (A,B) *atrial myosin heavy chain* (*amhc*; red; atrial marker) and *ventricular myosin heavy chain* (*vmhc*; purple; ventricular marker) were visualized by double in situ hybridization. (C,D) MF20 (red) and S46 (green) were visualized by whole mount immunofluorescence. (E,F) *bmp4* expression was examined by in situ hybridization. Ventricle (V), atrium (A) and outflow tract (OFT) are indicated. Arrows indicate the AV boundary, and the dotted line demarcates the cardiac silhouette. (G,H) Immunofluorescence was used to study *cmlc2*:GFP (green) and DM-GRASP (red) expression. Arrows and arrowheads indicate myocardium and endocardium, respectively. (I,J) Confocal analysis of the AV canal of control (I) and *hadp1* morphant (J) hearts shown in G,H. The superior (sup) and inferior (inf) aspects of the canal are shown, and remodeled trapezoidal cells are indicated with asterisks, whereas non-remodeled columnar cardiomyocytes are indicated with plus signs. Arrows and arrowheads indicate myocardium and endocardium, respectively. (K,L) *notch1b* expression was examined by in situ hybridization. Ventricle (V) and atrium (A) are indicated. Arrows indicate the AV boundary.](DMM002204F5){#f5-0040607}

DM-grasp enrichment in the AV cushion myocardium, observed in control-injected embryos (*n*=22; 100%) at 48 hpf, failed to occur in *hadp1* morphants (*n*=20; 0%) ([Fig. 5G,H](#f5-0040607){ref-type="fig"}) ([@b13-0040607]). Similarly, induction of DM-grasp expression within the AVC endocardium failed to occur in morphant embryos ([Fig. 5G,H](#f5-0040607){ref-type="fig"}). Furthermore, confocal microscopy on control embryos ([Fig. 5I,J](#f5-0040607){ref-type="fig"}) revealed the differentiated, trapezoidal cardiomyocyte morphology and cuboidal endocardial morphology previously reported ([@b13-0040607]). Of note, perhaps as a result of subtle timing differences, we failed to detect the previously reported lateral localization of DM-grasp within the AVC endocardium ([@b13-0040607]) in control ([Fig. 5I](#f5-0040607){ref-type="fig"}) or wild-type embryos (data not shown). In contrast to the control embryos, morphant embryos displayed an absence of DM-grasp expression in some AVC cardiomyocytes, abnormal localization of the protein and rectangular cardiomyocyte morphology in the superior portion of the AV canal, and a lack of DM-grasp expression within AVC endocardium. These data suggest that loss of *hadp1* leads to abnormal myocardial differentiation as determined by the failure to downregulate *bmp4* expression in the ventricle, the inability to upregulate *bmp4* within the AVC myocardium, and the altered myocardial cell morphology in the AVC.

Loss of *hadp1* perturbs Ca^2+^ handling in the heart
-----------------------------------------------------

Potential signals that could function to affect both cardiac performance and altered AVC differentiation as observed at maximal *hadp1* knockdown include electrical conduction and Ca^2+^ signaling ([@b22-0040607]; [@b30-0040607]; [@b68-0040607]). Thus, we examined the electrical properties of the heart as well as cardiomyocyte Ca^2+^ handling in the context of loss of Hadp1. Electrical impulse propagation is crucial for the synchronous contraction of the myocardium. Defects in excitation-contraction coupling can perturb contractile function without altering the initial structure or formation of the sarcomeric apparatus ([@b11-0040607]; [@b23-0040607]; [@b50-0040607]). To determine whether the effects on heart rate and contractility were associated with perturbation of cardiac electrical conduction, we performed optical voltage mapping of the heart at doses of MO that failed to elicit morphological defects (e.g. 2 ng) ([Fig. 6A](#f6-0040607){ref-type="fig"}) ([@b1-0040607]; [@b21-0040607]; [@b61-0040607]; [@b68-0040607]; [@b82-0040607]). There was evidence of significant prolongation of action potential duration \[APD80 (80% of the duration of an action potential in the heart)\] in SBMO1 morphant ventricles (234+11.3 ms vs 324+19.6 ms, *P*\<0.005), but not the atria (129.4+11.1 ms vs 156+16.3, not significant) ([Fig. 6B--E](#f6-0040607){ref-type="fig"}; supplementary material Movies 6, 7).

![**Ventricular cardiac electrical action potentials are affected in *hadp1* morphants.** (A--E) Optical mapping of voltage activation in the zebrafish heart. (A) Sequential images of an ex vivo wild-type heart at 48 hpf show the initiation of an electrical impulse from the sinoatrial (SA) node (left-side), as illustrated by the increased color in the left-most panel. Serial images show the propagation of electrical activation across the heart, through the atrium to the AV node, to the ventricle, and through the outflow tract. Lower panels, corresponding to those above, show the morphology of ventricular fluorescence during the course of a single round of impulse propagation. (B) Representative traces of action potentials from single sites in the atrium of control (black) and *hadp1* morphants (red). The atrial action potential duration (APD80) is quantified in C. (D) Representative traces of action potentials from single sites in the ventricle of control (black) and *hadp1* morphants (red). The ventricular action potential duration (APD80) is quantified in E.](DMM002204F6){#f6-0040607}

Given the perturbation of electrical function observed in *hadp1* morphant hearts, we turned our attention to Ca^2+^, a major effector of muscle contraction, and thus cardiac contractility. Using ratiometric Ca^2+^ imaging with Fura-2, we were able to characterize the effects of loss of *hadp1* on cardiomyocyte Ca^2+^ handling in the developing heart ([Fig. 7A](#f7-0040607){ref-type="fig"}). There was no significant effect of loss of *hadp1* on atrial diastolic Ca^2+^ concentrations \[0.94±0.10 arbitrary ratiometric units (r.u.) vs 0.89±0.11 r.u., not significant\] ([Fig. 7B,C](#f7-0040607){ref-type="fig"}), but there was a substantial increase in the prolongation of atrial transient amplitude and duration at doses of morpholino that exhibited no morphological effects (e.g. 2 ng) (duration: 157.0±11.6 ms vs 218.8±15.6 ms, *P*\<0.05: Ca^2+^ amplitude: 0.296±0.04 r.u. vs 0.397±0.06 r.u., *P*\<0.05) ([Fig. 7A--E](#f7-0040607){ref-type="fig"}). In ventricular cardiomyocytes we also identified a significant increase in the diastolic Ca^2+^ concentration in *hadp1* morphant hearts (0.73±0.09 r.u. vs 0.84±0.07 r.u., *P*\<0.05) ([Fig. 7A,B,F--H](#f7-0040607){ref-type="fig"}), and this was accompanied by a substantial increase in the amplitude and duration of the ventricular Ca^2+^ transient (duration: 233.0±32.4 ms and 309.7±17.3 ms, *P*\<0.05; Ca^2+^ amplitude: 0.175±0.07 r.u. vs 0.284±0.09 r.u., *P*\<0.05) ([Fig. 7A,G,H](#f7-0040607){ref-type="fig"}). These phenomena suggest that loss of *hadp1* leads to a reduced rate of extrusion of cytoplasmic Ca^2+^ during diastole with consequent effects on the duration of the Ca^2+^ transient and ultimately on the final diastolic Ca^2+^ concentration ([@b80-0040607]; [@b92-0040607]).

HADP1 interacts with PI4-kinase derivatives
-------------------------------------------

We sought to identify the biochemical pathway in which HADP1 acts to modulate Ca^2+^ handling. Because PH-domain-containing proteins and phosphoinositides can affect Ca^2+^ signaling, we determined whether the predicted PH domain of murine HADP1 (amino acids 164--184) could function as a bona fide phosphoinositide-interacting motif. Using a protein lipid overlay assay ([@b27-0040607]), we found that the PH domain of HADP1 bound to phosphatidylinositol 4-phosphate \[PI4P; also known as PtdIns(4)*P*\], phosphatidylinositol (4,5)-bisphosphate \[PI4,5P~2~; also known as PtdIns(4,5)*P*~2~\] and phosphatidylinositol (3,4,5)-trisphosphate \[PI3,4,5P~3~; also known as PtdIns(3,4,5)*P*~3~\] ([Fig. 8A](#f8-0040607){ref-type="fig"}). The PH domain also interacted with phosphatidic acid (PA) and cardiolipin. Similar results were obtained using the PH domain fused to maltose binding protein instead of GST (data not shown). Control assays performed in parallel indicated that the PH domain of AKT bound PI3,4,5P~3~, as previously reported ([@b32-0040607]; [@b46-0040607]) ([Fig. 8B](#f8-0040607){ref-type="fig"}).

Given the results suggesting that HADP1 can interact with phosphoinositides, we analyzed the subcellular localization of HADP1 in vitro to determine whether it might associate with the plasma membrane. Myc-epitope-tagged murine *Hadp1a* was expressed in HEK cells and was constitutively localized to the plasma membrane ([Fig. 8C](#f8-0040607){ref-type="fig"}). HADP1b was also constitutively localized to the plasma membrane (supplementary material Fig. S7), demonstrating that the membrane localization was not dependent upon the presence of the N-terminal WW motifs. Although in vitro binding studies indicated that the PH domain of HADP1 can interact with the plasma membrane phosphoinositide PI3,4,5P~3~, we found that HADP1 continued to be localized to the cell surface in cells depleted of PI3,4,5P~3~ by starvation (data not shown), suggesting that its localization is not PI3K dependent.

![**Ca^2+^ transient duration is altered following loss of *hadp1***. (A--H) Optical mapping and quantification of Ca^2+^ transients in the embryonic zebrafish heart. (A) Representative images of the mean Ca^2+^ transient amplitude following optical mapping, using the ratiometric dye Fura-2, in control and *hadp1* morphant hearts. The red box denotes an example of the pixel areas that were sampled for quantification of ventricular transients. The far-right scale indicates the transient amplitude intensity. (B) Representative traces of Ca^2+^ transients from single sites in the atrium and ventricle of control (black) and *hadp1* morphants (red). (C--E) Quantification of the atrial diastolic Ca^2+^ (C), transient amplitude (D) and transient duration (E). (F--H) Quantification of the ventricular diastolic Ca^2+^ (F), transient amplitude (G) and transient duration (H).](DMM002204F7){#f7-0040607}

To determine whether the PH domain was required for localization of HADP1, a construct harboring an in-frame deletion of the N-terminus (β1-β3 loop) of the PH domain was transfected into cells. This protein failed to localize to the plasma membrane and instead appeared in a peri-nuclear pool ([Fig. 8D](#f8-0040607){ref-type="fig"}). Subcellular fractionation and western blot analysis following transient transfection confirmed these results ([Fig. 8E](#f8-0040607){ref-type="fig"}). Higher resolution analysis by Percoll gradient fractionation determined that wild-type HADP1 was normally associated with membrane fractions (determined by the presence or absence of integrin β1, F1 ATPase and calregulin) ([Fig. 8F](#f8-0040607){ref-type="fig"}). The ΔPH mutant failed to be enriched in these fractions, but was still detected in the nuclear (unbroken) cell fraction (determined by lamin B reactivity), confirming the immunofluorescence results and demonstrating that the PH domain is required for the plasma membrane localization of HADP1 ([Fig. 8G](#f8-0040607){ref-type="fig"}).

From the biochemical and cell culture experiments, we hypothesized that HADP1 interacts with PI4K derivatives in vivo to regulate cardiac contractility. We employed pharmacological inhibition of PI4KIIIα (an enzyme responsible for the plasma membrane pools of PI4P and thus PI4,5P~2~) ([@b6-0040607]; [@b5-0040607]) activity to test this model. Corroborating our hypothesis, transient transfection of *Hadp1a-myc* and treatment with the PI4KIIIα inhibitor phenylarsine oxide (PAO) ([@b37-0040607]), followed by subcellular fractionation and western blotting, revealed that PI4KIIIα inhibition abolished membrane localization of HADP1a ([Fig. 8H](#f8-0040607){ref-type="fig"}). Furthermore, transient incubation of embryos with PAO beginning after the onset of circulation and cardiac contraction (24 hpf), resulted in diminished cardiac contractility at 48 hpf (supplementary material Fig. S8A). The decrease was dose-dependent and more profound than loss of *hadp1*, as might be expected given the wide range of cell signaling mediated by PI4K. Notably, PAO treatment also induced a dose-dependent prolongation of atrial and ventricular action potentials in embryonic hearts (supplementary material Fig. S8B,C). In addition, Ca^2+^ imaging revealed dose-dependent effects of PAO on atrial Ca^2+^ transient duration and amplitude, and ventricular Ca^2+^ handling parameters, that mirrored precisely the effects of SBMO1 ([Fig. 8I--K](#f8-0040607){ref-type="fig"}). Despite the comparable effects of SBMO1 and PAO, combining submaximal doses of the two failed to produce an additive effect on any Ca^2+^ handling parameters ([Fig. 8I--K](#f8-0040607){ref-type="fig"}).

DISCUSSION
==========

Owing to the interdependence of cardiac form and function in the developing heart, it is often difficult to discern whether a phenotype results primarily from altered cardiomyocyte morphogenesis, function or both. Studies of several mutants have shown that myocardial functions, specifically contractility and blood flow, are dispensable for initiation of the cardiogenic program and for the progression of early cardiac morphogenesis in zebrafish ([@b2-0040607]; [@b9-0040607]; [@b10-0040607]; [@b13-0040607]; [@b22-0040607]; [@b30-0040607]; [@b41-0040607]; [@b98-0040607]). Although commitment to the cardiac lineage, proliferation, chamber identity, looping, AVC restriction and Ca^2+^ handling occur normally in some functionally deficient mutants ([@b10-0040607]), development of the ECs ([@b97-0040607]) and the trabeculae ([@b21-0040607]; [@b72-0040607]) is abrogated in these mutants, suggesting that proper function is required for some aspects of myocardial differentiation during development, although a recent study might complicate this notion ([@b91-0040607]). Interestingly, several mutants that specifically affect EC formation \[*jekyll* (*ugdh*), *chys-1, klf2a*\] show normal cardiac morphogenesis and function through to 36 hpf, yet AVC development and later EC formation is lost, as is later cardiac function ([@b71-0040607]; [@b97-0040607]; [@b98-0040607]). These results, as hypothesized by Vermot and colleagues, suggest that the initial signaling events that induce cardiogenesis and AVC formation are genetically hardwired in the myocardium and independent of flow and contraction, but that these epigenetic forces are required for later steps in both endocardial and myocardial differentiation. Our analyses indicate that *hadp1* is dispensable for the establishment of the cardiac lineage and for early formation of the heart, but is required for normal cardiac function during embryogenesis (from 36 hpf onwards), for proper AVC formation. However, we found that, at doses of MO that do not affect overall morphogenesis of the heart, loss of *hadp1* still exhibited a dose-dependent effect upon both Ca^2+^ signaling within the heart and cardiac contractility.

![**PI4K activity is necessary for proper subcellular localization of HADP1 and affects Ca^2+^ transient duration.** (A,B) Membrane lipid overlay assay using the purified GST-PH domain of HADP1 (A) and AKT (B). (C,D) HEK293 cells were transiently transfected with myc-epitope-tagged *Hadp1* (C) or *Hadp1-ΔPH* (D), and, 36 hours later, were processed for indirect immunofluorescence with an antibody recognizing myc (green) and TOPRO3 (red) to label the nucleus. Arrows indicate cell membrane and peri-nuclear localization of WT and PH-domain mutant (ΔPH) HADP1-myc, respectively. (E) In parallel, these cells were subjected to subcellular fractionation and HADP1 was detected by western blotting with anti-myc antibodies. The membrane-enriched protein, integrin β1, was probed to confirm separation of fractionations. Input, total cell lysates; cyt, cytoplasmic fraction; mem, soluble membrane fraction. (F,G) Percoll gradient centrifugal density fractionation of HEK293 cells following transient transfection of *Hadp1-myc* (F) and *Hadp1-ΔPH-myc* (G). I/N, unlysed cells, nuclear-enriched fraction; lanes 1--13 are decreasing density fractions. Myc detects HADP1, integrin β1 labels the plasma membrane, lamin B labels the nuclear fraction, transketolase labels the cytoplasm, calregulin labels the endoplasmic reticulum and F1-ATPase labels the mitochondria. (H) Hadp1a-myc transiently transfected HEK293 cells were treated with PAO and subjected to subcellular fractionation, and HADP1 was detected by western blotting with anti-myc antibodies. The membrane-enriched protein integrin β1 and the nuclear-enriched protein lamin B were probed to confirm separation of fractionations. (I--K) Optical mapping and quantification of Ca^2+^ transients in the embryonic zebrafish heart. (I) Representative images of the mean Ca^2+^ transient amplitude following optical mapping, using the ratiometric dye Fura-2, in control, *hadp1* morphant and PAO-treated embryos. The control morphant and *hadp1* morphant data from [Fig. 7](#f7-0040607){ref-type="fig"} are included as a reference point for the interaction, and combined effect, of PAO activity on Ca^2+^ transient activity. The red box denotes an example of the pixel areas that were sampled for quantification of ventricular transients. The far-right scale indicates the transient amplitude intensity. (J,K) Representative traces of Ca^2+^ transients from single sites in the atrium and ventricle of embryos treated with control (black), SBMO1 (red), 0.5 μM PAO (green), 1.0 μM PAO (purple), SBMO1 + 0.5 μM PAO (blue) and SBMO1 + 1.0 μM PAO (orange).](DMM002204F8){#f8-0040607}

As the interplay between form and function is dissected, and as powerful tools emerge for exploring developmental physiology, another layer of functional complexity is beginning to be appreciated in the regulation of cardiac morphogenesis. Evidence suggests that electrical conduction regulates late, but not early, cardiomyocyte morphogenesis as well as differentiation independently of hemodynamic and contractile forces ([@b22-0040607]). We failed to observe morphological defects at doses of MO that clearly affect Ca^2+^ handling (although *hadp1* morphants do not beat asynchronously like the *cxn46* mutants). Using high-resolution video microscopy and optical voltage mapping we have demonstrated depression of cardiac contractility indices and a significant increase in ventricular action potential duration at 48 hpf following loss of *hadp1*. Concordantly, there was a significant increase in diastolic Ca^2+^ transient amplitude and transient duration in the ventricle at 48 hpf. Together, these findings suggest a defect in cytoplasmic Ca^2+^ extrusion in the normal sarcomeric reticulum (SR) release-reuptake cycle. These abnormalities in Ca^2+^ handling occur at doses of MO that do not affect cardiac morphogenesis, the initial establishment of cardiac chamber identity or AVC formation. Because *hadp1* loss also affects cardiac morphogenesis and myocyte differentiation at higher doses of MO, Ca^2+^ cycling might be a physiological input required for normal myocardial differentiation ([@b22-0040607]; [@b30-0040607]; [@b68-0040607]). However, we cannot rule out the possibility that Hadp1 affects intracellular Ca^2+^ handling independently of its effects on myocyte differentiation and morphogenesis.

There is evidence from others that HADP1 is a cytoplasmic component of the adherens junction (AJ) ([@b60-0040607]; [@b73-0040607]) and is required for AJ stability in human epithelial cells in vitro ([@b60-0040607]). Our immunofluorescence experiments confirm that murine HADP1a and/or HADP1b and zebrafish Hadp1 localize to the plasma membrane in multiple cell lines (data not shown), and our biochemical data establish that HADP1a co-fractionates with components of the plasma membrane. Together, these results implicate Hadp1 in the regulation of cell-cell coupling and the organization of adhesion complexes, including components such as connexins, in cardiomyocytes ([@b22-0040607]; [@b84-0040607]; [@b88-0040607]). Despite these inferences, our confocal analysis, TEM and gene expression analyses failed to reveal any myocyte adhesion defects, or the morphological abnormalities predicted to result from disruption of adhesion or AJ stability ([@b4-0040607]; [@b67-0040607]; [@b94-0040607]). Similarly, intercellular coupling (as assessed by in vivo imaging of myocardial action potential propagations) was unaffected, suggesting that AJ structure and coupling functions remain intact ([@b22-0040607]; [@b88-0040607]). Rather, our results point to an important role for HADP1 in the transduction of junctional signals through interaction with phosphoinositides and subsequent regulation of intracellular Ca^2+^ handling.

Intracellular Ca^2+^ signaling is a complex process with multiple independent compartments segregating discrete signals and communicating among themselves ([@b14-0040607]). Entry of Ca^2+^ from outside the cell is tightly regulated both by plasma membrane excitability and by signals from within the intracellular compartments. In the contracting cardiomyocyte, cycling of sarcomeric Ca^2+^ is regulated on a millisecond timescale by voltage-dependent Ca^2+^ channels, the consequent ryanodine receptor (RyR) Ca^2+^ release from the SR to mediate muscle contraction and subsequent active reuptake from the cytoplasm to SR, extracellular compartments or other compartments. An additional mode of internal Ca^2+^ release results from activation of phospholipase C (PLC) enzymes and their cleavage of PI4,5P~2~ to generate the second messengers DAG and Ins3,4,5P~3~. Inositol (1,4,5)-trisphosphate \[IP~3~; also known as Ins(1,4,5)*P*~3~\] binds and activates the IP~3~ receptors (IP~3~Rs) on the SR, which induces Ca2+ release and also sensitizes RyR. Of note, intracellular Ca^2+^ itself activates PLC ([@b29-0040607]). Several results have shown that, in addition to acting as a substrate for PI3,4,5P~3~ and IP~3~ generation, PI4,5P~2~ in the plasma membrane directly affects membrane charge and action potentials, and thus regulates intracellular Ca^2+^ ([@b7-0040607]; [@b35-0040607]; [@b40-0040607]). It has also been shown that PI4P is present within the mammalian plasma membrane ([@b6-0040607]). We have demonstrated that Hadp1 interacts with both PI4,5P~2~ and PI4P in vitro, and that its localization is dependent upon PI4K activity. Furthermore, loss of Hadp1 stimulates intracellular Ca^2+^ release and increased transient duration in the heart. From these observations, we hypothesize that Hadp1 normally functions to either inhibit both hydrolysis of PI4,5P~2~ and IP~3~-induced Ca2+ release, or to prevent phosphorylation of PI4P to generate PI4,5P~2~, which could affect IP~3~-induced Ca2+ release, regulation of reuptake of Ca^2+^ from the cytoplasm or plasma membrane Ca^2+^ conductance.

Although our findings confirm the involvement of phosphoinositides in normal embryonic cardiac function, they also suggest an important and, as of yet, undefined role for PI4K and its derivatives in these underlying processes. Indeed, we have recently shown that the patterning of Ca^2+^ compartments within the cardiomyocyte is itself highly complex, with paradoxical relationships emerging between specific intracellular Ca^2+^ pools ([@b68-0040607]). The precise balance of Ca^2+^ compartments might be important in specifying final cardiomyocyte differentiation. These same pathways are also known to play a major role in the regulation of physiological and pathological hypertrophy in adult hearts ([@b3-0040607]; [@b39-0040607]; [@b62-0040607]; [@b101-0040607]; [@b103-0040607]). Phosphoinositides, and the PH-domain-containing effector molecules that bind them, are also necessary and sufficient for the induction of pathological hypertrophy in mammalian cell culture and animal models ([@b19-0040607]; [@b24-0040607]; [@b48-0040607]; [@b57-0040607]; [@b56-0040607]; [@b75-0040607]; [@b85-0040607]; [@b87-0040607]). Recent studies suggest that PI4,5P~2~ might be involved in the adult hypertrophic response, because ablation of inositol polyphosphate-5-phosphatase f (*Inpp5f*) results in hypertrophy in adult mice, whereas cardiac-specific overexpression of *Inpp5f* renders mice resistant to agonist-induced cardiac hypertrophy ([@b95-0040607]; [@b104-0040607]). These findings suggest that the patterning of cardiac Ca^2+^ signaling is a central determinant of the developmental and adult responses required for adaptation to differing stressors. The work that we have presented establishes a central role for Hadp1 in the fundamental physiological transitions of myocardial development. In future studies it will be important to define the homeostatic mechanisms controlling the relationships between Hadp1-regulated Ca^2+^ signaling and other Ca^2+^ pools in healthy and diseased cardiomyocytes in fetal and adult models.

Methods
=======

Cloning of rat, mouse, human and zebrafish *Hadp1*
--------------------------------------------------

Rat *Hadp1* was cloned in a differential display screen ([@b63-0040607]). The murine homolog was identified in a cDNA library (a gift of Brigid Hogan, Duke University Medical Center, Durham, NC) and was used to generate riboprobes and expression constructs. The rat and mouse sequences were used in a BLAST search of the zebrafish EST database (ZV4; <http://www.ncbi.nlm.nih.gov/BLAST/>) to identify a potential zebrafish homolog. RT-PCR was performed using primers spanning the ESTs (Forward, 5′-TAGTAGAATTCACACGGGAATAATGGCGG-3′; Reverse, 5′-TAGCTCTAGACTGAACTGGCGTTTGAGCA-3′). The resultant 1.2-kb PCR fragment was extended by 5′ RACE (RLM-RACE kit, Ambion). The full-length open reading frame of zebrafish *hadp1* was obtained by RT-PCR (Forward, 5′-AGGGAATATGAGGTAGACAGC-3′; Reverse, 5′-CACAAGAATTAACCCTCGGACATGG-3′). All verified sequences have been submitted to Genbank (EU380770, EU380771, EU380772).

Embryo culture and zebrafish stock maintenance
----------------------------------------------

AB strain zebrafish *Danio rerio* were used as wild type. Embryos were generated, cultured and staged as described ([@b52-0040607]; [@b100-0040607]). Other lines used were Tg(*fli*:EGFP)^y1^ ([@b54-0040607]), and Tg(*cmlc2*:GFP) ([@b44-0040607]). Imaged embryos were grown in 0.002% 1-phenyl-2-thiourea to prevent pigment formation.

Analysis of gene expression
---------------------------

Northern analysis was performed as previously described ([@b63-0040607]). For WISH, zebrafish embryos were processed as previously described ([@b70-0040607]). Following WISH, embryos were dehydrated, embedded in a methacrolyte derivative and cut with a Leica 2055 rotary microtome.

Murine embryos were processed as previously described ([@b69-0040607]). In situ hybridized embryos were dehydrated, infiltrated with paraffin, embedded and 12-μm sections were counterstained with Nuclear Fast Red (Vector Labs).

Zebrafish *hadp1* riboprobe was constructed from a 1.2-kb fragment of the cDNA subcloned into pBS II SK. Murine *Hadp1* riboprobe was obtained by subcloning a fragment of the full-length cDNA into pBS II KS. Images were captured on a Leica MZ125 microscope.

MO knockdown of *hadp1* translation
-----------------------------------

Antisense MOs directed against *troponin T* ([@b83-0040607]), the exon 6 (encoding base pairs 428--532)/intron 6 splice donor site of *hadp1* (SBMO1: 5′-GATCAACTCTTAcctgcttgtaaag-3′) (intron in capitals, exon in lowercase), the exon 5 (encoding base pairs 332--428)/intron 5 splice donor site of *hadp1* (SBMO2: 5′-TTTGTTACTGAcctttgagcctgaa-3′) and a mismatch control oligo to SBMO1 (control MO: 5′-GATCAAGTGTTAgctgcttctaaag-3′), were obtained from Gene Tools, LLC (Corvalis, OR). MOs were dissolved in 1× Danieau's Buffer.

To detect *hadp1* transcripts, RT-PCR was performed on RNA from pools of 20 control-MO-, SBMO1- or SBMO2-injected embryos. *hadp1* was amplified by 25 cycles of PCR using primers in exon 4 (start at bp 262) (*hadp1* MO RT For: 5′-ACTACATTCATCCATCCAGTGACAGG-3′) and exon 7 (end at bp 570) (*hadp1* MO RT Rev: 5′-AAACCATTTTCTCTTCCACAACCG-3′). Amplicons were confirmed by DNA sequencing. β*-actin* (forward: 5′-CCCAAGGCCAACAGGGAAA-3′; reverse: 5′-GGT-GCCCATCTCCTGCTCAA-3′) was amplified from all samples to control for equal cDNA input.

Embryonic cardiovascular physiology
-----------------------------------

Circulation was scored by eye or under epifluorescence following microinjection of Rhodamine-dextran (10,000 MW; Sigma) into the CCV ([@b25-0040607]).

Analyses of heart rate, contractility and electrical function were performed at a dose of MO (1 ng and 2 ng) titrated to avoid the edema and other secondary effects observed at higher doses (10 ng). To measure heart rate, 48 hpf *cmlc2:*GFP transgenic embryos were equilibrated at 21°C, unless otherwise noted, and the fluorescent hearts were identified using the maximum subsite pixel intensities and 15-second video recordings obtained using a Nikon TE200 microscope and a Hamamatsu ORCA-ER camera. Fast-Fourier transform of the average pixel density over time was performed to determine heart rate. For drug treatment, an inhibitor of PI4K, PAO (Calbiochem) ([@b37-0040607]), was dissolved in DMSO, and dechorionated 24-hpf embryos were soaked in E3 media with 2.5 μM PAO or 0.1% DMSO for 24 hours, and heart rate was scored at 48 hpf.

Ventricular chamber size and contractile function was measured using noninvasive indices derived from videomicroscopy at high spatial and temporal resolution as previously described ([@b79-0040607]). For voltage mapping, individual hearts were isolated by microdissection in modified Tyrodes solution (136 mM NaCl, 5.4 mM KCl, 0.3 mM NaH~2~PO~4~, 1.8 mM CaCl~2~, 1 mM MgCl~2~, 5 mM glucose, 10 mM HEPES, 2% BSA). Cardiac motion was arrested with the myofibrillar ATPase inhibitor 2, 3-butanedione monoxime (Sigma) at 15--17 mM or with blebbistatin. Hearts were stained with a 7 μM solution of di-4-ANEPPS (Molecular Probes, Eugene, OR) for 10 minutes immediately prior to imaging. The preparations were placed in a custom pacing and imaging chamber and voltage mapping of spontaneous cardiac electrical activity was performed using this chamber and a CCD (CardioCCD-SMQ, RedShirtImaging, Decatur, GA) mounted on a Nikon TE2000 inverted microscope. The hearts were field paced with a square wave at 60 per minute (Grass S48K Stimulator, West Warwick, RI). Samples were illuminated using a 120 W metal-halide Exfo X-Cite 120 with a 480 nm/40 excitation filter and the fluorescence image filtered through a 535 nm/50 emission filter. Data were acquired at a frame rate of 125 Hz. Subsequent analyses were performed using Cardioplex software, including exponential subtraction of baseline photobleaching. Measurements of action potential durations were taken as the average of three or more successive beats for each sample. For all physiological studies, except the inhibitor experiments which used a two-sided *t*-test, statistical significance was determined by performing one-way analysis of variance (ANOVA) and the Tukey-Kramer post-test, assuming a normal distribution (PRISM4, Graphpad).

For ratiometric Ca^2+^ transient recordings, hearts were loaded for 15 minutes with 50 μM of the Ca^2+^-sensitive dye Fura-2, AM (Invitrogen) and subsequently washed in dye-free NT solution. Hearts were then incubated in NT solution at room temperature for 30--45 minutes to allow complete intracellular hydrolysis of the esterified dye. A high-speed monochromator (Optoscan, Cairn) was used to rapidly switch the excitation wavelength between 340 nm and 380 nm with a bandwidth of 20 nm and at a rate of 500 per second. The excitation light was reflected by a 400-nm cutoff dichroic mirror and fluorescence emission was collected by the camera through a 510/80 nm emission filter.

For the measurement of fluorescence intensities, we used a high-speed 80×80-pixel CCD camera (CardioCCD-SMQ, RedShirtImaging, LLC) with 14-bit resolution. Action potentials were recorded at the maximum frame rate of 2000 per second. For ratiometric Ca^2+^ transient recordings, monochromator and camera were synchronized. Because each wavelength change required a mechanical movement of the grating, the maximum frame rate for Ca^2+^ transient recordings was lower, i.e. 500 frames per second. Each ratio required the recording of four frames, where one frame was used for each transition between wavelengths. Thus, the final ratio rate was 125 per second. Using a 20×/0.75NA objective and a 0.5× C-mount adapter, the final magnification was 10×, resulting in a pixel-to-pixel distance of 2.2 μm.

Immunohistochemistry
--------------------

48-hpf embryos were processed for immunohistochemistry as reported elsewhere ([@b83-0040607]). Primary antibodies used were MF20 (1:2.5), S46 (1:2.5), Dm-GRASP (Zn8; 1:10) (Developmental Studies Hybridoma Bank), anti-GFP (1:400; Molecular Probes), H3P (1:100; Millipore). Secondary antibodies were goat-anti-mouse-IgG2b-TRITC (Southern Biotechnology), goat-anti-mouse-IgG1b-FITC (Southern Biotechnology), goat-anti-mouse-Alexa-Fluor-546 (Molecular Probes), goat-anti-rabbit-Alexa-Fluor-488 (Molecular Probes) and goat-anti-rabbit-Alexa-Fluor-546 (Molecular Probes) (all at 1:200). After staining, embryos were washed, re-fixed, mounted in 1% low-melt agarose on a 35 mm glass-bottom tissue culture dish (Mat Tek), and images were obtained on a DMRXE laser scanning confocal microscope (Leica). For DM-Grasp and H3P staining, embryos were embedded in agarose and sectioned by vibratome prior to confocal analysis. Tissue culture cells were processed as previously stated ([@b49-0040607]), using anti-myc (1:200), goat-anti-mouse-Alexa-Fluor-488 (10 mg/ml) and TOPRO-3 (2 μM) (Molecular Probes).

Scoring of vascular development
-------------------------------

*fli*:EGFP embryos were subjected to GFP immunohistochemistry and embedded in agarose as described above. Embryos that contained a DA, PCV, dorsal longitudinal anastomotic vessel, intersegmental vessels, intersegmental arteries and a parachordal vein as determined by confocal microscopy were scored as normal. Embryos lacking any of these structures were counted as abnormal.

Cardiomyocyte cell counting
---------------------------

Embryos were dissociated at 36 hpf as previously described ([@b86-0040607]), and *cmlc2:*GFP-positive cells were counted. 48-hpf intact hearts were imaged by confocal microscopy and cells counted for all planes sampled. For H3P staining in Tg(*cmlc2:*EGFP) embryos, vibratome sections of the heart were examined by confocal microscopy for double-positive red (H3P) and green (*cmlc2*:EGFP) cells. Unpaired *t*-test statistical analysis was performed assuming a normal distribution (PRISM).

Histology
---------

TEM was performed as previously described ([@b47-0040607]). For standard histology, 48-hpf embryos were fixed in 4% PFA overnight, dehydrated and processed as described ([@b31-0040607]). 5-μm sections were stained with Gill's hematoxylin (Sigma) and counterstained with an alcoholic eosin Y solution (Shandon).

In vitro studies
----------------

Early passage HEK293 and HEK293T cells were routinely passaged before they reached 75% confluency. 1.2×10^6^ cells were seeded onto poly-L-lysine-coated 6-cm dishes and transfected the next day with 3 μg of the appropriate plasmid DNA using FUGENE-6 (Roche). Cells were harvested 36 hours later in 1 ml of hypotonic lysis buffer (10 mM Tris-HCl, pH 7.4, 5 mM KCl, 1 mM DTT, 1 mM MgCl~2~, protease inhibitors), and homogenized in a dounce homogenizer. Homogenates were spun at 400 ***g*** for 10 minutes to remove nuclei and the supernatant was subsequently spun at 16,000 ***g*** for 30 minutes and saved as the cytosolic fraction. The pellet was resuspended in RIPA and re-spun at 16,000 ***g***, and the supernatant was saved as the soluble membrane fraction. For Percoll gradient fractionation, cells seeded on poly-L-lysine-coated 10-cm dishes were transfected with 10--20 μg of DNA. 24--48 hours later, cells were washed in PBS, then scraped in 5 ml ice-cold 1× PBS/1 mM DTT/protease inhibitors, and the cells were pelleted. The cells were resuspended in 2.5 ml of 250 mM sucrose/50 mM Tris-pH 7.4/5 mM MgCl~2~/0.5 mM EDTA/1 mM DTT/protease inhibitors and then lysed in a ball-bearing homogenizer. Nuclei, and unlysed cells, were pelleted (400 ***g*** for 10 minutes at 4°C; swinging bucket rotor). The pellet was washed and resuspended in 20 mM HEPES pH 7.9/1.5 mM MgCl~2~, 0.5 M NaCl/0.2 mM EDTA/20% glycerol/1% Triton. The supernatant was then loaded onto a 7.5 ml, 27% Percoll cushion and spun in a Ti41 fixed angle rotor at 30,000 rpm at 4°C for 30 minutes. The sample was then eluted in 750 μl fractions, mixed 1:1 with 2× sample buffer and loaded on a 4--15% gradient SDS-PAGE gel. Western analysis was performed as previously stated ([@b49-0040607]). Antibodies used were anti-myc (9E10), anti-lamin-B, anti-calregulin, anti-transketolase, anti-F1-ATPase, anti-β-tubulin (Santa Cruz), anti-β1-integrin (BD Transduction Labs), and goat-anti-mouse or rabbit HRP (Jackson Labs).

###### TRANSLATIONAL IMPACT

### Clinical issue

Cardiogenesis requires a tightly regulated interplay between cell signaling events, epigenetic factors and transcriptional regulation to ultimately form a three-dimensional, fully functioning heart. The fact that congenital heart disease (CHD) is the most common type of inherited birth defect illustrates the complexity of this integrated process: some form of CHD is observed in 1 in every 100 live births. Many forms of CHD include defects in the electrical conduction system and in valve morphogenesis. Although electrical conduction and Ca^2+^ handling in the adult heart are well understood, little is known about how these functional characteristics are established and maintained in the embryonic heart, and how they impact cardiac morphogenesis and differentiation.

### Results

To identify unknown regulators of embryonic cardiac development and function, the authors of this study performed a screen for genes that are differentially expressed during embryonic and postnatal heart development. They report the identification and characterization of a newly identified gene, heart adaptor protein 1 (*Hadp1*), which is conserved from zebrafish to humans. *Hadp1* expression is enriched in the vertebrate embryonic heart and, in zebrafish embryos, loss of *hadp1* expression disrupts cardiac function in a dose-dependent manner by altering Ca^2+^ handling. In addition, *hadp1* zebrafish morphants exhibit contractility defects and aberrant differentiation of the chamber and non-chamber myocardium. In vitro experiments indicate that HADP1 is a membrane-bound pleckstrin-homology-domain protein that interacts with phosphatidylinositol derivatives. Finally, the authors present in vivo pharmacological data implicating phosphatidylinositol 4-kinase (PI4K) as an upstream regulator of Hadp1 function in the embryonic heart, and suggesting that PI4K signaling and Ca^2+^ interact to regulate embryonic heart morphogenesis and function.

### Implications and future directions

These results characterize *Hadp1* as a new regulator of cardiac function and morphogenesis during embryogenesis. Further investigation of the role of HADP1, as well as that of PI4K signaling, might shed light on the function of a heretofore unappreciated relationship between phosphatidylinositol signaling and Ca^2+^ dynamics in cardiac differentiation, conduction, embryonic development and disease.

Binding studies
---------------

The coding sequence of the PH domain of murine HADP1 (amino acid 164--184) was amplified by PCR (For: 5′-ATTTCATTCAGTAAAGTGCACAGCTTCGG-3′/Rev: 5′-ATGATGATGCGGCCGCACGTGGCCACATTCTTGG-3′), digested with *Eco*RI and *Not*I, and ligated into pGEX-4T1 (Amersham). The Akt-PH-GST plasmid was a gift of Dario Alessi, University of Dundee, UK. Plasmids were transformed into Rosetta 2 (DE3, pLysS-) competent cells (Novagen) and recombinant protein was purified according to standard methods. Protein was dialyzed into PBS/2 mM DTT/20% glycerol and stored at −80°C.

PIP strips (Echelon Biosciences) were blocked with TBS-Tween (TBST)/0.1% ovalbumin (OAB) (Sigma) for 1 hour at room temperature then incubated with 1.0 μg/ml of recombinant GST-fusion protein in TBST/OAB overnight at 4°C. The membrane was then washed in TBST, probed with anti-GST (1:2000; Sigma) at 4°C for 2 hours, washed in TBST, then incubated with goat-anti-mouse HRP (1:10,000), washed and detected by ECL (Amersham).
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